41
Participants
Start Date
November 1, 2011
Primary Completion Date
August 1, 2013
Study Completion Date
March 1, 2015
Doxazosin
Doxazosin were prepared as opaque capsules by a compounding pharmacy and inserted into blister packs. Consistent with the recommended titration, doxazosin was titrated up to 16 mg daily (or maximum tolerable dose) during the first 4 weeks. A 1-week downward titration for safety reasons was also planned. Study medication adherence was assessed by self-report and pill count. Additionally, capsules contained 25mg riboflavin as a marker of adherence through urine sample.
Placebo
Matched placebo were prepared as opaque capsules by a compounding pharmacy and inserted into blister packs. Consistent with the recommended titration, doxazosin or matched placebo was titrated up to 16 mg daily (or maximum tolerable dose) during the first 4 weeks. A 1-week downward titration for safety reasons was also planned. Study medication adherence was assessed by self-report and pill count. Additionally, capsules contained 25mg riboflavin as a marker of adherence through urine sample.
Brown University Center for Alcohol and Addiction Studies, Providence
Brown University Center for Alcohol and Addiction Studies, Providence
Lead Sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Brown University
OTHER